Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery


A Phase III,Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel, Multicenter Study Evaluating the Efficacy and Safety of Dexmedetomidine in the Prevention of Postoperative Delirium in Subjects Undergoing Surgery for Fractured Hip With General Anesthesia




Dexmedetomidine is currently approved for use for 24 hours in patients on ventilators in the ICU. This study is to determine whether or not dexmedetomidine can prevent delirium after hip fracture repair surgery. Study participation will last from within 72 hours of surgery to 3 days after surgery, continue throughout surgery and up to 2 hours after surgery. Delirium will be assessed prior to surgery and for 72 hours after surgery. This assessment will consist of questions to determine memory and thought process. Thirty days after surgery, questions will be asked regarding quality of life and hospital billing.

Study Status: Terminated


Condition Intervention Phase
Delirium Drug: Dexmedetomidine Phase 3

Verified by Hospira, Inc. November, 2007

Sponsored by: Hospira, Inc.
Information provided by: Hospira, Inc. identifier: NCT00460473

Study Type: Interventional

Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site